Skip to main content

Table 4 Effect of VSL#3® on fibrosis risk scores

From: A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

  Number of patients pre-VSL#3® Number of patients post-VSL#3® p valuea
F0–F2 Indeterminate F3–F4 F0–F1 Indeterminate F3–F4  
NAFLD fibrosis risk score 1 11 7 3 9 7 0.16
FIB4 index 8 7 4 8 9 2 0.41
  1. n = 19
  2. F0–F2 = absence of significant fibrosis
  3. F3–F4 = presence of significant fibrosis
  4. aWilcoxon signed rank test